EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and βcatenin to foster vascular integrity during experimental diabetes

Current Neurovascular Research

Volumn 8, Issue 2, 2011, Pages 103-120

  Chong, Zhao Zhong ^a,b   Hou, Jinling ^a,b   Shang, Yan Chen ^a,b   Wang, Shaohui ^a,b   Maiese, Kenneth ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b New Jersey Medical School University Hospital Cancer Center   (United States)

Author keywords

Akt1; Apoptosis; Cytokines; Diabetes; Endothelial; Erythropoietin; Forkhead; FoxO3a; Growth factors; GSK 3 ; Oxidative stress; Phosphatidylserine; Protein kinase B; Wnt.; catenin

Indexed keywords

BETA CATENIN; CASPASE; CELL NUCLEUS DNA; CYTOCHROME C; ERYTHROPOIETIN; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLSERINE; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1; WNT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CELL; CELL MEMBRANE; CELL NUCLEUS; CELL TRANSPORT; CONTROLLED STUDY; CYTOPLASM; DIABETES MELLITUS; DNA DEGRADATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL DIABETES MELLITUS; GENE SILENCING; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; VASCULAR BIOLOGY;

EID: 79955731167     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720211795495402     Document Type: Article

References (114)

1. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298(7):765-75. (Pubitemid 47263159)
2. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr 2009; 19(1):20-4.
3. Hao J, Shen W, Tian C, et al. Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J Cell Mol Med 2009; 13(4):701-11.
4. Maiese K. Triple play: Promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomed Pharmacother 2008; 62(4):218-32. (Pubitemid 351635845)
5. Maiese K, Chong ZZ, Shang YC, Hou J. Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus. J Clin Pharmacol 2010 Mar 10.
6. Maiese K, Morhan SD, Chong ZZ. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 2007; 4(1):63-71. (Pubitemid 46280293)
7. Maiese K, Shang YC, Chong ZZ, Hou J. Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res 2010 ; 7(1):59-64.
8. Wu SY, Wang GF, Liu ZQ, et al. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol Sin 2009; 30(2):202-8.
9. Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol 2004; 26(8):1044-80. (Pubitemid 39577337)
10. Maiese K, Chong ZZ, Hou J, Shang YC. New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev 2009 ; 2(5):279-89.
11. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53(9):1937-42.
12. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010 ; 17(34):4256-69.
13. Shaik NA, Shaik JP, Ali S, Imran A, Rao DK. Increased frequency of micronuclei in diabetes mellitus patients using pioglitazone and glimepiride in combination. Food Chem Toxicol 2010; 48(12):3432-5.
14. Maiese K. Diabetic stress: new triumphs and challenges to maintain vascular longevity. Expert Rev Cardiovasc Ther 2008 ; 6(3):281-4.
15. Perkins BA, Bril V. Diagnosis and management of diabetic neuropathy. Curr Diab Rep 2002; 2(6):495-500.
16. Sonnen JA, Larson EB, Brickell K, et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol. 2009 ; 66(3):315-22.
17. Niiya Y, Abumiya T, Shichinohe H, et al. Susceptibility of rain microvascular endothelial cells to advanced glycation end productsinduced tissue factor upregulation is associated with intracellular reactive oxygen species. Brain Res. 2006; 1108(1):179-87. (Pubitemid 44278013)
18. Huber JD, VanGilder RL, Houser KA. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am J Physiol Heart Circ Physiol 2006;291(6):H2660-8. (Pubitemid 44904065)
19. Chong ZZ, Kang JQ, Maiese K. AKT1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3, and 9. Exp Cell Res 2004 ;296(2):196-207. (Pubitemid 38624641)
20. Chong ZZ, Lin SH, Maiese K. Nicotinamide Modulates Mitochondrial Membrane Potential and Cysteine Protease Activity during Cerebral Vascular Endothelial Cell Injury. J Vasc Res 2002; 39(2):131-47. (Pubitemid 34507639)
21. L'Episcopo F, Tirolo C, Testa N, et al. Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis 2011 ; 41(2):508-27.
22. Li F, Chong ZZ, Maiese K. Vital elements of the wnt-frizzled signaling pathway in the nervous system. Curr Neurovasc Res 2005; 2(4):331-40. (Pubitemid 41297370)
23. Li F, Chong ZZ, Maiese K. Winding through the WNT pathway during cellular development and demise. Histol Histopathol 2006 ; 21(1):103-24. (Pubitemid 43033719)
24. Maiese K, Li F, Chong ZZ, Shang YC. The Wnt signaling pathway: Aging gracefully as a protectionist? Pharmacol Ther 2008 ;118(1):58-81.
25. Shahjee HM, Koch KR, Guo L, Zhang CO, Keay SK. Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res 2010; 29:160.
26. Chong ZZ, Maiese K. Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. Histol Histopathol 2004 ; 19(2):495-504. (Pubitemid 38443910)
27. Chong ZZ, Shang YC, Hou J, Maiese K. Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. Oxid Med Cell Longev 2010 ; 3(2):153-65.
28. Smalley MJ, Dale TC. Wnt signalling in mammalian development and cancer. Cancer Metastasis Rev 1999; 18(2):215-30. (Pubitemid 30043859)
29. Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K, Wang FS. Wnt/beta-catenin signaling modulates survival of high glucosestressed mesangial cells. J Am Soc Nephrol 2006 ;17(10):2812-20. (Pubitemid 44484671)
30. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006 ; 38(3):320-3.
31. Wright WS, Longo KA, Dolinsky VW, et al. Wnt10b Inhibits Obesity in ob/ob and Agouti Mice. Diabetes 2007 ; 56(2):295-303.
32. Kanazawa A, Tsukada S, Sekine A, et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet 2004 ; 75(5):832-43. (Pubitemid 39390490)
33. Bournat JC, Brown AM, Soler AP. Wnt-1 dependent activation of the survival factor NF-kappaB in PC12 cells. J Neurosci Re. 2000 ; 61(1):21-32. (Pubitemid 30436471)
34. Chong ZZ, Li F, Maiese K. Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal 2007 ; 19(6):1150-62. (Pubitemid 46561553)
35. Shang YC, Chong ZZ, Hou J, Maiese K. Wnt1, FoxO3a, and NFkappaB oversee microglial integrity and activation during xidantV stress. Cell Signal 2010 ; 22(9):1317-29.
36. Chong ZZ, Shang YC, Maiese K. Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res. 2007 Aug;4(3):194-204. (Pubitemid 47235971)
37. He B, Reguart N, You L, Mazieres J, et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005 ; 24(18):3054-8. (Pubitemid 40675537)
38. You L, He B, Uematsu K, et al. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res 2004 ; 64(10):3474-8. (Pubitemid 38657920)
39. Goodwin AM, D'Amore PA. Wnt signaling in the vasculature. Angiogenesis. 2002;5(1-2):1-9. (Pubitemid 36076918)
40. Venkatesan B, Prabhu SD, Venkatachalam K, et al. WNT1- inducible signaling pathway protein-1 activates diverse cell survival pathways and blocks doxorubicin-induced cardiomyocyte death. Cell Signal 2010 ; 22(5):809-20.
41. Wang Z, Havasi A, Gall JM, Mao H, Schwartz JH, Borkan SC. Beta-catenin promotes survival of renal epithelial cells by inhibiting Bax. J Am Soc Nephrol 2009 ; 20(9):1919-28.
42. Balaraman Y, Limaye AR, Levey AI, Srinivasan S. Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol Life Sci 2006; 63(11):1226-35. (Pubitemid 43939009)
43. Chong ZZ, Li F, Maiese K. Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and beta-Catenin During Oxidative Stress. Curr Neurovasc Res 2006; 3(2):107-17. (Pubitemid 43764787)
44. Wilusz M, Majka M. Role of the Wnt/beta-catenin network in regulating hematopoiesis. Arch Immunol Ther Exp (Warsz) 2008; 56(4):257-66.
45. Mussmann R, Geese M, Harder F, et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. J Biol Chem 2007; 282(16):12030-7. (Pubitemid 47100714)
46. Yue TL, Bao W, Gu JL, et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005; 54(2):554-62.
47. Maiorana A, O'Driscoll G, Goodman C, Taylor R, Green D. Combined aerobic and resistance exercise improves glycemic control and fitness in type 2 diabetes. Diabetes Res Clin Pract May; 56(2):115-23.
48. Wilson C, Hargreaves M, Howlett KF. Exercise does not alter subcellular localization, but increases phosphorylation of insulinsignaling proteins in human skeletal muscle. Am J Physiol Endocrinol Metab 2006; 290(2):E341-6.
49. Maiese K, Chong ZZ, Li F, Shang YC. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008; 85(2):194-213.
50. Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev 2008 ; 19(2):145-55.
51. Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004; 25(11):577-83. (Pubitemid 39371148)
52. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. Jama 2005; 293(1):90-5. (Pubitemid 40066704)
53. Murua A, Orive G, Hernandez RM, Pedraz JL. Emerging technologies in the delivery of erythropoietin for therapeutics. Med Res Rev 2011; 31(2):284-309.
54. Ponikowski P, Jankowska EA. EPO's rescue mission in acute myocardial infarction: still more hopes than evidence. Eur Heart J 2010; 31(21):2577-9.
55. Taniguchi N, Nakamura T, Sawada T, et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 2010; 74(11):2365-71.
56. Canadillas S, Ortega R, Estepa JC, et al. Darbepoetin-alpha treatment enhances glomerular regenerative process in the Thy-1 glomerulonephritis model. American journal of physiology 2010; 299(6):F1278-87.
57. Dang J, Jia R, Tu Y, Xiao S, Ding G. Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother 2010; 64(10):681-5.
58. Deng A, Arndt MA, Satriano J, et al. Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade. American journal of physiology. 2010; 299(6):F1365-73.
59. Maiese K, Chong ZZ, Hou J, Shang YC. The vitamin nicotinamide: translating nutrition into clinical care. Molecules 2009; 14(9):3446-85.
60. Ogino A, Takemura G, Kawasaki M, et al. Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia. J Am Coll Cardiol 2010; 56(23):1949-58.
61. Lai MC, Yang SN. Perinatal hypoxic-ischemic encephalopathy. J Biomed Biotechnol 2011; 2011:609813.
62. Walden AP, Young JD, Sharples E. Bench to bedside: A role for erythropoietin in sepsis. Crit Care 2010; 14(4):227.
63. Chauhan NB, Gatto R. Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury. Brain Res 2010; 1360: 177-92.
64. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106(23):2973-9. (Pubitemid 35424751)
65. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, Cytochrome c, and Caspase-9 Form the Critical Elements for Cerebral Vascular Protection by Erythropoietin. J Cereb Blood Flow Metab 2003; 23(3):320-30. (Pubitemid 36307576)
66. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 2003;138(6):1107-18. (Pubitemid 36459833)
67. Chong ZZ, Li F, Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res 2005;2(5):387-99. (Pubitemid 41789605)
68. Pappo O, Ben-Ari Z, Shevtsov E, et al. The role of excessive versus acute administration of erythropoietin in attenuating hepatic ischemia-reperfusion injury. Can J Physiol Pharmacol 2010;88(12):1130-7.
69. Velly L, Pellegrini L, Guillet B, Bruder N, Pisano P. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword? Pharmacol Ther 2010; 128(3):445-59.
70. Wierzbowska J, Robaszkiewicz J, Figurska M, Stankiewicz A. Future possibilities in glaucoma therapy. Med Sci Monit 2010; 16(11):RA252-9.
71. Mojiminiyi OA, Abdella NA, Zaki MY, El Gebely SA, Mohamedi HM, Aldhahi WA. Prevalence and associations of low plasma erythropoietin in patients with Type 2 diabetes mellitus. Diabet Med 2006; 23(8):839-44. (Pubitemid 44141071)
72. Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, Leotsinidis M, Kyriazopoulou V, Vassilakos P, et al. Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol 2006; 85(2):79-85. (Pubitemid 43085303)
73. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol. 2005 Feb;75(3):207-46. (Pubitemid 40693131)
74. Chong ZZ, Li F, Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 2005; 49(1):1-21. (Pubitemid 40800161)
75. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18(1):141-6. (Pubitemid 36104490)
76. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 200; 102(4):1340-6.
77. Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 2007; 150(7):839-50. (Pubitemid 46536625)
78. Abbott NJ, Hughes CC, Revest PA, Greenwood J. Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci 1992; 103 ( Pt1):23-37.
79. Hou J, Chong ZZ, Shang YC, Maiese K. FoxO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrino. 2010;321(2):194-206.
80. Hou J, Chong ZZ, Shang YC, Maiese K. Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovasc Res 2010; 7(2):95-112.
81. Kang JQ, Chong ZZ, Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol 2003; 64(3):557-69. (Pubitemid 37048558)
82. Kang JQ, Chong ZZ, Maiese K. Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J Neurosci Res 2003;74(1):37-51. (Pubitemid 37176665)
83. Balan V, Miller GS, Kaplun L, et al. Life span extension and neuronal cell protection by Drosophila nicotinamidase. J Biol Chem 2008; 283(41):27810-9.
84. Chong ZZ, Maiese K. Enhanced Tolerance against Early and Late Apoptotic Oxidative Stress in Mammalian Neurons through Nicotinamidase and Sirtuin Mediated Pathways. Curr Neurovasc Res 2008; 5(3):159-70.
85. Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med 2008; 14(5):219-27.
86. Chong ZZ, Li F, Maiese K. The pro-survival pathways of Mtor and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med 2007; 19(2):263-72.
87. Eldar-Finkelman H, Argast GM, Foord O, Fischer EH, Krebs EG. Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells. Proc Natl Acad Sci U S A 1996; 93(19):10228-33. (Pubitemid 26314604)
88. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 2007; 14(16):1729-38. (Pubitemid 47163410)
89. Pagano G, Bargero G, Vuolo A, Bruno G. Prevalence and clinical features of known type 2 diabetes in the elderly: a population-based study. Diabet Med 1994; 11(5):475-9. (Pubitemid 24210267)
90. Chong ZZ, Lin SH, Kang JQ, Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res 2003; 71(5):659-69. (Pubitemid 36255350)
91. Li F, Chong ZZ, Maiese K. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factorkappaB. Curr Neurovasc Res 2006; 3(3):187-201. (Pubitemid 44198472)
92. Mason-Garcia M, Beckman BS, Brookins JW, et al. Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney Int 1990 ; 38(5):969-75. (Pubitemid 20362871)
93. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005;45(9):1406-12. (Pubitemid 40615610)
94. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006; 118(3):e635-40. (Pubitemid 46089988)
95. Sohmiya M, Kakiba T, Kato Y. Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. Eur J Endocrinol 1998; 139(4):367-70. (Pubitemid 28494079)
96. Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 2008; 14(12):1357-62.
97. Chong ZZ, Kang J, Li F, Maiese K. mGluRI Targets Microglial Activation and Selectively Prevents Neuronal Cell Engulfment Through Akt and Caspase Dependent Pathways. Curr Neurovasc Res 2005; 2(3):197-211. (Pubitemid 40980179)
98. Jessel R, Haertel S, Socaciu C, Tykhonova S, Diehl HA. Kinetics of apoptotic markers in exogeneously induced apoptosis of EL4 cells. J Cell Mol Med 2002; 6(1):82-92. (Pubitemid 44133985)
99. Mallat M, Marin-Teva JL, Cheret C. Phagocytosis in the developing CNS: more than clearing the corpses. Curr Opin Neurobiol 2005; 15(1):101-7. (Pubitemid 40249968)
100. Dentice M, Marsili A, Ambrosio R, et al. The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. J Clin Invest 2010; 120(11):4021-30.
101. Wilk A, Urbanska K, Yang S, et al. Insulin-like growth factor-Iforkhead box O transcription factor 3a counteracts high glucose/tumor necrosis factor-alpha-mediated neuronal damage: implications for human immunodeficiency virus encephalitis. J Neurosci Res 2011 ; 89(2):183-98.
102. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 2010; 5(12):e15627.
103. Maiese K, Chong Z, Hou J, Shang Y. The "O" Class: Crafting clinical care with FoxO transcription factors. Adv Exp Med Biol 2009; 665:242-60.
104. Cheng Z, White MF. Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal 2011; 14(4):649-61.
105. Maiese K, Chong ZZ, Shang YC, Hou J. FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond) 2009; 116(3):191-203.
106. Maiese K, Hou J, Chong ZZ, Shang YC. A fork in the path: Developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev 2009; 2(3):119-29.
107. Storz P. Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid Redox Signal 201;14(4):593-605.
108. Maiese K, Chong ZZ, Shang YC, Hou J. Clever cancer strategies with FoxO transcription factors. Cell Cycle 2008; 7(24):3829-39.
109. Maiese K, Chong ZZ, Shang YC, Hou J. A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev 2009; 29(3):395-418.
110. Shang YC, Chong ZZ, Hou J, Maiese K. The forkhead transcription factor FoxO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res 2009; 6(1):20-31.
111. Shang YC, Chong ZZ, Hou J, Maiese K. FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr Neurovasc Res 2009; 6(4):223-38.
112. El-Mir MY, Detaille D, G RV, Delgado-Esteban M, et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 2008; 34(1):77-87. (Pubitemid 351378091)
113. Newsholme P, Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and nonmitochondrial ROS production and activity. J Physiol 2007; 583(Pt 1):9-24. (Pubitemid 47244241)
114. Plecita-Hlavata L, Lessard M, Santorova J, Bewersdorf J, Jezek P. Mitochondrial oxidative phosphorylation and energetic status are reflected by morphology of mitochondrial network in INS-1E and HEP-G2 cells viewed by 4Pi microscopy. Biochim Biophys Acta 2008 ; 1777(7-8):834-46.